Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

2014 Annual Meeting | 2CO.001 - Research and Technology Colloquium: From Discovery to Therapy

Sunday 04/27/14
08:00 AM - 12:00 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Colloquium
Wendy R. Galpern, MD, PhD, FÂ鶹´«Ã½Ó³»­
Attendees should have an increased understanding of the steps involved in drug discovery and development as well as the challenges inherent to each stage. Additionally, attendees will learn about associated regulatory requirements.
No CME available
Trainee, General Neurologist, Specialist Neurologist, Non-neurologist
Didactic, Interactive, Audience Participation
Event Timeline
08:00 AM - 08:10 AM Introduction
Wendy R. Galpern, MD, PhD, FÂ鶹´«Ã½Ó³»­
08:10 AM - 08:40 AM Discovery of Novel Therapeutic agents for CNS Disorders: Target Selection and Discovery Process
Peter J. Conn, PhD
08:40 AM - 09:10 AM Translating Scientific Discovery into a Novel Therapy in the Academic Setting
Charles A. Thornton, MD, FÂ鶹´«Ã½Ó³»­
09:10 AM - 09:40 AM Early Stage Development: Decisions and Challenges
Steven M. Paul, MD
09:40 AM - 09:55 AM Break
09:55 AM - 10:25 AM Late Stage Development: Decisions and Challenges
Ira Shoulson, MD
10:25 AM - 10:55 AM Development of Cell and Gene Therapies
Wilson W. Bryan, MD
10:55 AM - 11:25 AM Discussion
11:25 AM - 11:55 AM Questions and Answers
11:55 AM - 12:00 PM Wrap-Up and Summary
Wendy R. Galpern, MD, PhD, FÂ鶹´«Ã½Ó³»­
Faculty Disclosures
Wendy R. Galpern, MD, PhD, FÂ鶹´«Ã½Ó³»­ No disclosure on file
Charles A. Thornton, MD, FÂ鶹´«Ã½Ó³»­ Dr. Thornton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avidity. Dr. Thornton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Thornton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis. Dr. Thornton has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne. Dr. Thornton has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pepgen. The institution of Dr. Thornton has received research support from Marigold Foundation. The institution of Dr. Thornton has received research support from NIH. The institution of Dr. Thornton has received research support from Muscular Dystrophy Association . The institution of Dr. Thornton has received research support from Dyne. The institution of Dr. Thornton has received research support from Avidity. The institution of Dr. Thornton has received research support from Ionis. Dr. Thornton has received intellectual property interests from a discovery or technology relating to health care.
Ira Shoulson, MD Dr. Shoulson has received research support from Vaccinex.
Wilson W. Bryan, MD Dr. Bryan has received personal compensation in the range of $100,000-$499,999 for serving as a Director, Office of Tissues and Advanced Therapies with United States Food and Drug Administration (FDA).
Peter J. Conn, PhD No disclosure on file
Steven M. Paul, MD No disclosure on file